Zieba A, Grannas K, Soderberg O et al (2012) Molecular tools for companion diagnostics. N Biotechnol 29:634–640

Article  CAS  PubMed  Google Scholar 

Mosele MF, Westphalen CB, Stenzinger A et al (2024) Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol 35:588–606

Article  CAS  PubMed  Google Scholar 

Loong HH, Shimizu T, Prawira A et al (2023) Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group. ESMO Open 8:101586

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ebi H, Bando H (2019) Precision oncology and the Universal Health Coverage System in Japan. JCO Precis Oncol. https://doi.org/10.1200/PO.19.00291

Article  PubMed  PubMed Central  Google Scholar 

Ganjoho service. https://ganjoho.jp/public/qa_links/report/statistics/2022_en.html Accessed Aug 2024

Kohno T, Kato M, Kohsaka S et al (2022) C-CAT: the national datacenter for cancer genomic medicine in Japan. Cancer Discov 12:2509–2515

Article  PubMed  PubMed Central  Google Scholar 

Garfeld S, Douglas MP, MacDonald KV et al (2015) Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology. Per Med 12:13–22

Article  PubMed  PubMed Central  Google Scholar 

Meric-Bernstam F, Brusco L, Shaw K et al (2015) Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 33:2753–2762

Article  PubMed  PubMed Central  Google Scholar 

Statz CM, Patterson SE, Mockus SM (2017) Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic. Expert Rev Mol Diagn 17:549–555

Article  CAS  PubMed  Google Scholar 

Ohmoto A, Hayashi N, Fukada I et al (2022) Druggable gene alterations in Japanese patients with rare malignancy. Neoplasia 33:100834

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato S, Kurasaki K, Ikeda S et al (2018) Rare tumor clinic: the University of California San Diego Moores Cancer Center experience with a precision therapy approach. Oncologist 23:171–178

Article  CAS  PubMed  Google Scholar 

Thapa B, Ahmed G, Szabo A et al (2023) Comprehensive genomic profiling: does timing matter? Front Oncol 13:1025367

Article  PubMed  PubMed Central  Google Scholar 

Ito Y, Miyashiro I, Ito H et al (2014) Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci 105:1480–1486

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483

Article  CAS  PubMed  Google Scholar 

Ray-Coquard I, Pautier P, Pignata S et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381:2416–2428

Article  CAS  PubMed  Google Scholar 

Li N, Zhu J, Yin R et al (2023) Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial. JAMA Oncol 9:1230–1237

Article  PubMed  PubMed Central  Google Scholar 

Mbatani N, Olawaiye AB, Prat J (2018) Uterine sarcomas. Int J Gynaecol Obstet 143(Suppl 2):51–58

Article  PubMed  Google Scholar 

Hay MA, Severson EA, Miller VA et al (2020) Identifying opportunities and challenges for patients with sarcoma as a result of comprehensive genomic profiling of sarcoma specimens. JCO Precis Oncol. https://doi.org/10.1200/PO.19.00227

Article  PubMed  PubMed Central  Google Scholar 

Yoshino K, Kurita T, Takahashi F et al (2023) Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: annual patient report for 2020 and annual treatment report for 2015. J Obstet Gynaecol Res 49:2584–2592

Article  PubMed  Google Scholar 

Xi Q, Kage H, Ogawa M et al (2023) Genomic landscape of endometrial, ovarian, and cervical cancers in Japan from the database in the center for cancer genomics and advanced therapeutics. Cancers (Basel) 16:136

Article  PubMed  Google Scholar 

Shirota H, Komine K, Takahashi M et al (2023) Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: a retrospective observational study. Cancer Med 12:6170–6181

Article  CAS  PubMed  Google Scholar 

Kondo T, Matsubara J, Quy PN et al (2021) Comprehensive genomic profiling for patients with chemotherapy-naive advanced cancer. Cancer Sci 112:296–304

Article  CAS  PubMed  Google Scholar 

Kikuchi J, Ohhara Y, Takada K et al (2021) Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan. Jpn J Clin Oncol 51:753–761

Article  PubMed  Google Scholar 

Prieto-Potin I, Idrovo F, Suarez-Gauthier A et al (2022) Comprehensive approach to genomic and immune profiling: insights of a real-world experience in gynecological tumors. Diagnostics (Basel) 12:1903

Article  CAS  PubMed  Google Scholar 

Hayashi N, Mori S, Ohmoto A et al (2024) Availability of genome-matched therapy based on clinical practice. Int J Clin Oncol 29:964–971

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maruthi VK, Khazaeli M, Jeyachandran D et al (2022) The clinical utility and impact of next generation sequencing in gynecologic cancers. Cancers (Basel) 14:1352

Article  CAS  PubMed  Google Scholar 

Huang M, Hunter T, Slomovitz B et al (2019) Impact of molecular testing in clinical practice in gynecologic cancers. Cancer Med 8:2013–2019

Article  PubMed  PubMed Central  Google Scholar